Scarica l'app Stockscreener
0.7717
4.42%
-0.0357
Dopo l'orario di chiusura:
.77
-0.0017
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon Appoints Ivan Cheung to Board of Directors - citybiz
Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India
Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance
Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat
Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India
What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times
Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews - Benzinga
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlig - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Lexicon: Q3 Earnings Snapshot - The Washington Post
FMR LLC's Strategic Acquisition of Lexicon Pharmaceuticals Shares - GuruFocus.com
LXRXLexicon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings: EPS of -$0. - GuruFocus.com
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Previ - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Jefferies London Healthcare Conference | LXRX Stock News - StockTitan
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals - Benzinga
HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 - The Manila Times
Pharma Stock Has Significant Upside Potential, Analyst Says - Streetwise Reports
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss - StockTitan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Hold” Rating at Needham & Company LLC - Defense World
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - MSN
FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread - The Pharma Letter
Lexicon stock in selloff on FDA AdCom rebuke (LXRX:NASDAQ) - Seeking Alpha
Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote - MarketWatch
Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners - StreetInsider.com
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - The Manila Times
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters.com
FDA advisers vote against Lexicon Pharma’s add-on drug for type 1 diabetes - PharmaLive
Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication - Citeline News & Insights
Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista — Update - Morningstar
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista - Morningstar
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):